[[{“value”:”In the UK, Moderna has started a trial for an exploratory mRNA “vaccine” for cancer.
Patients at Imperial College Healthcare NHS Trust received the therapy, which makes use of technology from the COVID- 19 shots.
According to Imperial College London, cancer patients in the UK are receiving a new healing to assist their bodies in recognizing and combating cancer cells as part of an international trial.
Moderna’s brand-new mRNA cancer vaccine was tested on British patients at https ://t.co/d1jbNkKTad.
On February 4, 2024, Living Forever ( @LivingForever8 )
Imperial College London made the following announcement:
As part of a phase 1/2 medical trial, the second UK patients received experimental mRNA therapy at Imperial College Healthcare NHS Trust. MRNA- 4359 is an immunological treatment. The purpose of the trial is to assess the drug’s safety and efficacy in treating melanoma, lung cancer, and other” solid tumor” cancers.
The treatment works by giving the patient’s immune system common tumor markers. It is created using messenger RNA ( mRNA ). In addition to possibly eliminating cells that might stifle the immune response, this should aid in teaching patients ‘ immune systems to recognize and combat cancer cells expressing these markers.
According to Imperial College London,” these exploratory mRNA cancer immunotherapies incorporate popular marker proteins found in tumours,” in contrast to the COVID- 19 vaccines, which trained immune cells using a protein on the outside of the virus.
Cancer vaccine trials unleash the biological circus in the UK, according to Moderna’s mRNA madness! t.co/df4sEQwA2S
— Chris Wick News, February 4, 2024 (@ChrisWickNews )
Unbiased reports:
In some cases, vaccines are developed especially for the patient in the lab using their own hereditary data, while in other instances, they are more broadly targeted at particular cancer types.
In the most recent development, American patients are testing a vaccine called mRNA-4359 as part of an early-stage clinical trial that will first examine both safety and effectiveness.
People with superior melanoma, lung cancer, and other good tumor cancers are targeted for the vaccine.
The second person from the UK to receive the vaccine at Hammersmith Hospital in late October was an 81-year-old man who is a participant in the trial arm run by Imperial College London and Imperial Council Healthcare NHS Trust.
The man from Surrey has malicious melanoma skin cancer that is not responding to treatment and does not want to be named.
The only thing I did n’t have, he said, was chemotherapy.” I had a different immunotherapy, I had radiotherapy. Therefore, there were two options: wait and do nothing, or get involved and take action.
The vaccine will be tested both single and in combination with an active medication called pembrolizumab, which is an approved immunotherapy treatment and is even known as Keytruda, according to the release.
Among the numerous mRNA products in Moderna’s pipeline are dozens like rRNA-4359.
The biotechnology company is creating transcriptional therapies for conditions like the Zika virus, influenza, RSV, HIV, Lyme disease, and others.
HERE is a link to Moderna’s entire transcriptional pipeline.”}]] [[{“value”:”
Moderna has started a trial in the United Kingdom for an experimental mRNA “vaccine” for cancer.
Imperial College Healthcare NHS Trust administered the therapy to patients, which uses technology from COVID-19 injections.
Imperial College London reported that “Cancer patients are receiving a new treatment to help their bodies recognize and fight cancer cells in a global trial.”
New mRNA cancer vaccine from Moderna trialed in British patients https://t.co/d1jbNkKTad
Living Forever (@LivingForever8), February 4, 2024
Imperial College London announces:
As part of a phase 1 clinical trial, the first UK patients were treated with mRNA therapy. This is a type immunotherapy treatment known as mRNA-4359. The trial is evaluating its safety and potential to treat melanoma and lung cancer, as well as other cancers that are classified as’solid tumours’.
The treatment uses messenger RNA (mRNA), which works by presenting common tumour markers to the patient’s immunity system. This will help train the patient’s immune system to recognize and fight cancer cells that express these markers. It may also eliminate cells which suppress the immune response.
Imperial College London reported that “whereas the COVID-19 vaccinations trained immune cells by using mRNA from a protein found on the outside of the viral, these experimental mRNA immunotherapies for cancer incorporate mRNA from common marker proteins present in tumours.”
Moderna’s mRNA madness: Cancer vaccine trials unleash genetic circus in the UK! https://t.co/df4sEQwA2S
Chris Wick News (@ChrisWickNews), February 4, 2024
Independent reports:
Some vaccines are made specifically for patients in the laboratory using their genetic information. Others are more generalized vaccines that target specific types of cancer.
British patients are currently testing a vaccine named mRNA-4359 in an early-stage trial that will first look at safety and effectiveness.
The vaccine is intended for people with advanced melanoma and lung cancer, as well as other solid tumours.
A 81-year old man who is participating in the Imperial College London and Imperial College Healthcare NHS Trust trial arm was the first UK patient to receive the vaccine in Hammersmith Hospital at the end of October.
The man from Surrey who did not want to be identified has malignant melanoma, a type of skin cancer that does not respond to treatment.
He said: “I’ve had a different type of immunotherapy, radiotherapy and the only thing that I didn’t get was chemotherapy. The options were to either wait and do nothing, or to get involved and take action.
The outlet reported that during the trial the vaccine would be tested both alone and in combination of an existing drug, pembrolizumab. This is an immunotherapy treatment approved by the FDA, also known as Keytruda.
Moderna has dozens of mRNAs in its pipeline, including mRNA-4359.
The biotechnology company develops mRNA treatments for influenza, RSV and HIV, Lyme disease as well as Zika virus.
Moderna’s complete mRNA pipeline is available HERE.
“}]]
